Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-primed DC Vaccine Adjuvant Treatment in Advanced Cancers
NCT04147078Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Jun 2019
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neoantigen-primed dendritic cell vaccine in gastric cancer (GC), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC) and 1 more, sponsored by Sichuan University. Primary endpoint: Disease-free Survival at 5 years. Started Jun 2019; status: recruiting.
02
Drugs
neoantigen-primed dendritic cell vaccine
03
Conditions
gastric cancer (GC)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04147078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147078.